 price
us system and/or complianc
pipelin stori
 retain preview singl page exhibit
beta test report season post
feedback ad addit exhibit granular
cf execut phase last week fda approv trikafta
uk/nh agreement tick box major cf
catalyst turn cf franchis execut
stori consensu evr isi cf revenu expect
shown exhibit point us street
expect rapid trikafta kalydeco-lik adopt big
question mind question
rais april initi cf patient
significantli biggest unappreci upsid potenti
cf franchis view row expect eu price
remain effect opaqu black box factor post
street may abl start back eu report
rev assum patient number get effect portfolio
price interestingli investor survey show higher
buy-sid eu price expect exhibit part
eu price thesi assumpt remain unchang
exhibit retain eu estim street
even right eu price actual matter
stock ww cf estim consensu
number top bottom line high qualiti
compound-annual-growth-rate howev even stock
bull conced significantli break year trade
rang cap need deliv upsid current
expect ys pipelin stori
pipelin focal point upsid note
enviabl posit high qualiti doubl digit growth
till least thu time build broad earli stage
pipelin applaud strategi via mix
organ toolbox deal exhibit part expect
deal near futur note buy-sid focu
program pre survey exhibit part
provid pipelin summari tabl exhibit next
pipelin catalyst crsp partner -thal scd
preliminari safeti efficaci data expect
see link detail preview pictur
price increas previous
made variou housekeep chang financi includ
earli launch trikafta move ev/sal base
target price basi tp repres
premium peer group ev/sal revenue estim
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
survey result pipelin becom increas focu row cf reimburs
overhang clear major investor view price attain
investor survey result cf still
focu hurdl rate still high
major investor vs
expect higher sell side
higher
sell-side
sell-side
sell-side
fewer bear vs
lower
rel import variou
factor move stock
cf/ex-u reimburs biggest near term
focu
pain
assum
trikafta fda approv drove stock
upper end rang stock rang
bound last month break
visibl ex-u reimburs
tripl post launch need
expected/no visibl
clearli increas investor focu
pipelin pain piib repres
medicaid exposur henc
macro chang materi effect
domain domin cf franchis make
consensu long central in-lin
rate april initi
consensu eu cf
revenu estim post
revenu estim turn due
observ impli
consensu eu cf price
 us
next-gen competit pipelin
unless materi
els row reimbur pipelin
timelin materi updat unclear
us access virtual elig pt
sever shot goal diversifi cf
target dmd
mrna therapeut inhal cf tx
advanc
preliminari
estim evaluatepharma indic overal
sever meaning updat across program scd pain fsg cf
phase know
toplin acut bunionectomi
neuropath musculoskelet oa pain
said self-commerci acut pain
neuropath pain opportun specialti sale forc
look partner commerci musculoskelet
bunionectomi dose-rang studi data pend
investig multipl molecul besid
initi novel inhibitor
first pt dose sever sickl cell diseas
-thal first pt dose
four month follow engraft
dose studi sad mad
second molecul advanc ftd receiv
preclin molecul look good term safeti
efficaci pk formul ddi advanc molecul
program differenti vs aso replac
treat liver lung patholog aso
liver replac lung also oral vs
unspecifi in-licens earli stage asset rho inhibitor
initi
addit inhibitor preclin dev
promis preclin canin data gene-edit
once-daili cf corrector purchas
dose-rang studi on-going support potenti qd
combo next-gen corrector tezakaftor
on-going note receiv ftd
wait data
decid
one move
preliminari safeti
crsp pr
advanc
pt z-z
mutat data
expect
liken cf
small number
pt short
activ may
liver biopsi
protein level urin
beyond
initi
studi
on-going research collab identifi dev
on-going research collab
even work treat lung cf
think far-
year fruition
exhibit vertex stock trade deserv sector high multipl peer
signific valuat justifi premium growth howev revenu number lower consensu
magnitud even lower number qualiti cf
revenu secur decad warrant sector-high
multipl even expand
howev view asymmetr downsid risk
consensu revenu number reflect in-lin
evercor isi research data factset
exhibit evr-isi cf estimate vs lower due lower row
lower year cf number driven lower eu price assumpt
deviat
see wood tree overal eu final elig cf
orkb/sym major no-go
tripl con impli
price per patient assumpt individu eu countri cf
price averag across patient indic individu
importantli use penetr rate eu patient
popul us patient popul year per
origin invest thesi approach let assum overal
patient popul us eu eu price
top ly drug uk vs impli cf franchis tripl launch
preclin data candid advanc clinic
ev/sales-bas valuat premium vs revenue-gener biotech peer group
ex-u reimburs cystic fibrosi product price pressur market product pipelin risk
articl articl
time dissemin octob
analyst ravi mehrotra vivek sivathanu primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
